NCT02808650 2023-12-20
Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
Children's Oncology Group
Phase 1 Completed
Clinical Trials
4 trialsNCT02873975 2022-10-21
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03414047 2022-08-19
A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
Eli Lilly and Company
Phase 2 Completed
NCT02735980 2020-03-17
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed